LawLinter
Back to search
S 331 - 119

HALT Fentanyl Act

Became Public Law No: 119-26.

Bill highlights

Votes, text signals, source context, and latest movement from this record.

House votes
Passed Roll call 166
On Passage
321
Yea
104
Nay
0
Present
7
NV
View votes
Source context
Linked data

1 sector · 1 CBO estimate · spending context · campaign finance context

Review context
Bill text
17
analyzed sections
10 deadlines
Open stats
Latest action
Jul 16, 2025

Signed by President.

View timeline

Bill Text Stats

17
Analyzed sections
N/A
Detected dollar total
0
Tax signals
10
Deadlines

Signal counts

Tax density 0.0%
Spending density 0.0%
Statutory Reference 38
Amendments 13
Deadline 10
Rulemaking 7
Studies 2
Agency 1
Enforcement 1

Top agencies

Secretary of Health and Human Services 1

Statutory references

21 U.S.C. 822 6
21 U.S.C. 823 4
Public Law 117-328 4
21 U.S.C. 355 2
21 USC 812 2
21 USC 822 2
21 U.S.C. 960 2
21 U.S.C. 355 1

House Votes

Roll call 166 · Session 1 · Jun 12, 2025
On Passage
Passed
321
Yea
104
Nay
0
Present
7
NV

Timeline

Jul 16, 2025

Signed by President.

Jul 16, 2025

Signed by President.

Jul 16, 2025

Became Public Law No: 119-26.

Jul 16, 2025

Became Public Law No: 119-26.

Jul 8, 2025

Presented to President.

Jul 8, 2025

Presented to President.

Jun 12, 2025

Considered as unfinished business. (consideration: CR H2806)

Jun 12, 2025

Passed/agreed to in House: On passage Passed by the Yeas and Nays: 321 - 104 (Roll no. 166). (text: 6/11/2025 CR H2625-2627)

Jun 12, 2025

On passage Passed by the Yeas and Nays: 321 - 104 (Roll no. 166). (text: 6/11/2025 CR H2625-2627)

Jun 12, 2025

Motion to reconsider laid on the table Agreed to without objection.

Jun 11, 2025

Considered under the provisions of rule H. Res. 489. (consideration: CR H2625-2633)

Jun 11, 2025

Rule provides for consideration of H.R. 884, H.R. 2056, H.R. 2096 and S. 331. The resolution provides for consideration of H.R. 884, H.R. 2056, H.R. 2096, and S. 331 under a closed rule with one hour of general debate for each bill. The resolution provides for one motion to recommit on H.R. 884, H.R. 2056, and H.R. 2096, and one motion to commit on S. 331.

Jun 11, 2025

DEBATE - The House proceeded with one hour of debate on S. 331.

Jun 11, 2025

The previous question was ordered pursuant to the rule.

Jun 11, 2025

POSTPONED PROCEEDINGS - At the conclusion of debate on S. 331, the Chair put the question on passage of the bill and by voice vote, announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.

Jun 10, 2025

Rule H. Res. 489 passed House.

Jun 9, 2025

Rules Committee Resolution H. Res. 489 Reported to House. Rule provides for consideration of H.R. 884, H.R. 2056, H.R. 2096 and S. 331. The resolution provides for consideration of H.R. 884, H.R. 2056, H.R. 2096, and S. 331 under a closed rule with one hour of general debate for each bill. The resolution provides for one motion to recommit on H.R. 884, H.R. 2056, and H.R. 2096, and one motion to commit on S. 331.

Mar 18, 2025

Received in the House.

Mar 18, 2025

Held at the desk.

Mar 14, 2025

Considered by Senate. (consideration: CR S1762-1765)

Mar 14, 2025

The committee substitute agreed to by Unanimous Consent.

Mar 14, 2025

Passed/agreed to in Senate: Passed Senate with an amendment by Yea-Nay Vote. 84 - 16. Record Vote Number: 127.

Mar 14, 2025

Passed Senate with an amendment by Yea-Nay Vote. 84 - 16. Record Vote Number: 127.

Mar 14, 2025

Message on Senate action sent to the House.

Mar 13, 2025

Cloture on the measure invoked in Senate by Yea-Nay Vote. 84 - 15. Record Vote Number: 124. (CR S1735)

Mar 13, 2025

Considered by Senate. (consideration: CR S1735)

Mar 11, 2025

Considered by Senate. (consideration: CR S1659)

Mar 11, 2025

Cloture motion on the measure presented in Senate. (CR S1659)

Mar 10, 2025

Motion to proceed to measure considered in Senate. (CR S1623)

Mar 10, 2025

Motion to proceed to consideration of measure agreed to in Senate by Voice Vote. (consideration: CR S1623)

Mar 10, 2025

Measure laid before Senate by motion.

Mar 6, 2025

Motion to proceed to measure considered in Senate. (CR S1596)

Mar 6, 2025

Cloture on the motion to proceed to the measure invoked in Senate by Yea-Nay Vote. 82 - 12. Record Vote Number: 110. (CR S1596)

Mar 5, 2025

Motion to proceed to measure considered in Senate. (CR S1521)

Mar 4, 2025

Motion to proceed to consideration of measure made in Senate. (CR S1488)

Mar 4, 2025

Cloture motion on the motion to proceed to the measure presented in Senate. (CR S1488)

Mar 3, 2025

Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

Mar 3, 2025

Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

Mar 3, 2025

Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.

Feb 27, 2025

Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

Jan 30, 2025

Introduced in Senate

Jan 30, 2025

Read twice and referred to the Committee on the Judiciary.

Affected Sectors

How to read this

Sectors are deterministic matches from official Congress.gov data and cached bill text. They are source-derived signals, not conclusions about intent or economic effect.

Evidence matches count official fields, normalized subjects, cached text snippets, or extracted entities that matched the sector rules.

Impact is a bill-level rollup used for sorting and filtering. It is not an economic impact estimate.

Confidence is the strongest individual match score behind that sector.

Evidence snippets show why a sector matched and can repeat when Congress.gov repeats the same phrase across official fields.

Healthcare
103 evidence matches
Impact 100% Confidence 82%

Secretary of Health secretary of health

Secretary of Health and Human secretary of health and human

Secretary of Health and Human Services secretary of health and human services

CBO Cost Estimates

Official Congressional Budget Office cost estimate links associated with this bill through Congress.gov records.

How to read this

CBO estimates are official source documents with their own assumptions, scope, and publication dates. They can score a bill, a version of a bill, or a broader legislative package.

LawLinter stores the source link from Congress.gov and does not replace the CBO document. Use these cards as pointers for source review, not as independent fiscal advice.

CBO context shows source-attributed Congressional Budget Office cost estimates linked from official Congress.gov bill records. It is research context only; read the official CBO source document for assumptions, scope, and dates.

Implementation and spending context

Official USAspending.gov award records for agencies connected through bill-text agency signals. This can help review implementation-adjacent public spending context, but it is not proof that the law caused a specific award.

How to read this

USAspending records describe federal awards, grants, contracts, loans, direct payments, recipients, agencies, and dates reported through the official public spending system.

LawLinter links this context through agency names detected in bill text. That bridge is a research shortcut and should not be read as a legal or budget conclusion.

USAspending context shows official public award records for agencies connected through LawLinter bill-text agency signals. It is historical spending and award context only, not proof that this bill caused, authorized, required, or changed any award, grant, contract, payment, or program spending.

Agency sample by amount

Where the local sample is concentrated

$146.2B
Department of Health and Human Services $146.2B
569 sampled awards

Amounts reflect the local USAspending sample linked through agency text signals, not bill-caused spending.

Largest sampled awards

Award records in this context

MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES $18.8B
grants · Department of Health and Human Services
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES $17.6B
grants · Department of Health and Human Services
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES $17.5B
grants · Department of Health and Human Services
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES $16.2B
grants · Department of Health and Human Services
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES $16.1B
grants · Department of Health and Human Services
DEPARTMENT OF EDUCATION CALIFORNIA $2.3B
grants · Department of Health and Human Services

These bars summarize the visible sampled awards below so large awards are easier to scan.

Agency spending context

Department of Health and Human Services

Matched bill text signal: Secretary of Health and Human Services
Sampled awards569
Award amount in local sample$146,150,587,987
Open official USAspending agency page

Campaign Finance Context

Related FEC/OpenFEC campaign-finance records for lawmakers and candidates tied to this bill through source-attributed legislative relationships. These are not donations to the bill itself.

How to read this

Amounts shown here are campaign-finance totals for sponsor or cosponsor-linked candidates and their committees in the displayed FEC cycle.

They are not donations to this bill, spending on this bill, or proof that money influenced or caused sponsorship, cosponsorship, votes, or legislative outcomes.

If multiple linked lawmakers have FEC records, this section can show multiple candidate cards and separate sponsor/cosponsor rollups.

Campaign-finance context uses source-attributed FEC/OpenFEC records that are related or relevant to the displayed bill, lawmaker, candidate, committee, or legislative relationship through deterministic links. It is research context only, not proof of influence, causation, endorsement, or that money caused a sponsorship, vote, or legislative outcome.

Candidate campaign summary

S6FL00640

S · FL-00 · REPUBLICAN PARTY
2026 cycle
Campaign receipts$14,524,032
Individual total$6,832,682
Committee total$2,404,500
Cosponsor · confidence 92%
Campaign committee

MOODY FOR FLORIDA

C00895763 · Senate
Principal committee
Committee receipts · 2026 cycle$14,511,860
Disbursements$13,695,978
Cosponsor: 1

Lobbying Context

Related LDA.gov filings where public lobbying activity descriptions reference this bill. These records are source-attributed research context, not evidence of influence or causation.

How to read this

LDA filings are public lobbying disclosure records. LawLinter links them here only when the filing activity text contains an exact-looking reference to this bill.

A filing can mention many issues, clients, agencies, or bills. A match should be treated as a pointer for review, not as a conclusion about why legislation changed or how any lawmaker acted.

Lobbying context uses source-attributed LDA.gov records that appear related to this bill through bill references in public lobbying activity descriptions. It is research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.

No LDA.gov lobbying disclosure context is currently linked for this bill.

Summary

49 Public Law Jan 27, 2026

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

00 Introduced in Senate Mar 5, 2025

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the bill establishes a new, alternative registration process for certain schedule I research. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the bill expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

Sponsors

Cassidy, Bill
Sponsor

Cassidy, Bill

Republican · LA-6 · C001075

Joined Jan 30, 2025
Website
N/A
Phone
(202) 224-5824
Office
455 Dirksen Senate Office Building Washington, DC 20510
Daines, Steve
Cosponsor

Daines, Steve

Republican · MT-0 · D000618

Joined Jan 30, 2025
Website
N/A
Phone
(202) 224-2651
Office
320 Hart Senate Office Building Washington, DC 20510
Gallego, Ruben
Cosponsor

Gallego, Ruben

Democratic · AZ-7 · G000574

Joined Jan 30, 2025
Website
N/A
Phone
(202) 224-4521
Office
302 Hart Senate Office Building Washington, DC 20510
Kennedy, John
Cosponsor

Kennedy, John

Republican · LA · K000393

Joined Jan 30, 2025
Website
N/A
Phone
(202) 224-4623
Office
437 Russell Senate Office Building Washington, DC 20510
Schmitt, Eric
Cosponsor

Schmitt, Eric

Republican · MO · S001227

Joined Jan 30, 2025
Website
N/A
Phone
(202) 224-5721
Office
404 Russell Senate Office Building Washington, DC 20510
Britt, Katie Boyd
Cosponsor

Britt, Katie Boyd

Republican · AL · B001319

Joined Feb 3, 2025
Website
N/A
Phone
(202) 224-5744
Office
416 Russell Senate Office Building Washington, DC 20510
Hawley, Josh
Cosponsor

Hawley, Josh

Republican · MO · H001089

Joined Feb 3, 2025
Website
N/A
Phone
(202) 224-6154
Office
381 Russell Senate Office Building Washington, DC 20510
Tillis, Thomas
Cosponsor

Tillis, Thomas

Republican · NC · T000476

Joined Feb 3, 2025
Website
N/A
Phone
(202) 224-6342
Office
113 Dirksen Senate Office Building Washington, DC 20510
Justice, James C.
Cosponsor

Justice, James C.

Republican · WV · J000312

Joined Mar 6, 2025
Website
N/A
Phone
(202) 224-3954
Office
509 Hart Senate Office Building Washington, DC 20510
McCormick, David
Cosponsor

McCormick, David

Republican · PA · M001243

Joined Mar 6, 2025
Website
N/A
Phone
(202) 224-6324
Office
702 Hart Senate Office Building Washington, DC 20510
Ricketts, Pete
Cosponsor

Ricketts, Pete

Republican · NE · R000618

Joined Mar 6, 2025
Website
N/A
Phone
(202) 224-4224
Office
139 Russell Senate Office Building Washington, DC 20510
Hyde-Smith, Cindy
Cosponsor

Hyde-Smith, Cindy

Republican · MS · H001079

Joined Mar 11, 2025
Website
N/A
Phone
(202) 224-5054
Office
528 Hart Senate Office Building Washington, DC 20510

Amendments

35 amendments
119/samdt/1237 Mar 14, 2025

To improve the bill.

Considered by Senate. (consideration: CR S1765)

Show 23 more amendments 35 total amendments
Compiled bill record. Bill pages combine Congress.gov source payloads, normalized relationships, cached text analysis, vote links, and deterministic sector/signal extraction. This is not an official government record or legal advice; use the official source link when accuracy matters.
DisclaimerReport issue